BioSpace News Archive

Lentiviral vectors find utilization as a medium to make a delivery of foreign genetic material into a separate cell.

The drive for leukapheresis devices market stems from the need for improving therapeutic leukapheresis for the management of hyperleukocytosis and/or leukostasis.

Sexually transmitted diseases, also referred as venereal diseases are infections that can pass from person to person during sex.

Platelet Rich Plasma therapy is used for boosting the healing of injuries on an individual’s body. Effective healing of various injuries such as tennis elbow, hamstring, rotator cuff, tendon injuries, and others brings efficient growth prospects for the U.S. platelet rich plasma market across the forecast period of 2019-2029.

Transparency Market Research has published a new report titled, ‘Mobile Imaging Services Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

According to the report, the global pelvic floor electrical stimulation devices market was valued at US$ 300 Mn in 2019 and is projected to expand at a CAGR of 9.5% from 2020 to 2030.

Vaccination is one of the most cost-effective and safest ways to prevent diseases. Pneumococcus is one of the major causes of blood infection, pneumonia, sinusitis, meningitis, and otitis media.

Gunze Limited [TOKYO:3002] is pleased to announce that Gunze’s biodegradable scaffolds are being provided to the Abigail Wexner Research Institute at Nationwide Children’s Hospital to conduct its first human tissue engineered vascular grafts, clinical trial.

A Nomination Committee consisting of members appointed by the three largest shareholders or group of shareholders and the Chairman of the Board of Directors has been formed for Biotage AB in accordance with the principles adopted by the annual general meeting held on 4 June 2020.

KYAN Therapeutics, Inc., a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors.